India’s GLP-1 weight-loss drug market crosses ₹2,000 crore
India’s weight-loss drug market grew from ₹565 crore in May 2025 to more than ₹2,000 crore by June 2026, fuelled by semaglutide generics, greater awareness and wider access. The rapid rise also heightens the need for medically supervised use and long-term safety monitoring.
India’s GLP-1 weight-loss drug market crossed ₹2,000 crore in June 2026, driven by affordable semaglutide generics, awareness and wider access. The category grew 237% year-on-year, though doctors stressed medically supervised use and long-term safety monitoring.
Why this matters
No related recent signals are listed. The market’s rapid expansion aligns with accelerating retail-brand activity and raises the importance of supervised prescribing and safety follow-up.
Retail-brand activity is accelerating, up +347900% quarter over quarter.